Cara Therapeutics (CARA) – Momentum Movers
-
Cara Therapeutics (CARA) gains 25% after-hours following FDA approval of KORSUVA
-
Needham & Company Maintains Bullish View on Cara Therapeutics (CARA) Following IV CR845 License Agreement
-
-
-
-
Back to CARA Stock Lookup